Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
13.56
+0.05 (0.37%)
At close: Aug 13, 2025, 4:00 PM
14.00
+0.44 (3.24%)
Pre-market: Aug 14, 2025, 8:47 AM EDT

Mineralys Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
28.3623.8214.35.232.420.53
Research & Development
174.71168.5870.3626.2516.312.41
Operating Expenses
203.07192.484.6631.4818.732.94
Operating Income
-203.07-192.4-84.66-31.48-18.73-2.94
Interest Expense
-----0.03-0.12
Interest & Investment Income
12.314.5912.761.68--
Other Non Operating Income (Expenses)
-00.01000-0.37
EBT Excluding Unusual Items
-190.77-177.81-71.9-29.8-18.75-3.43
Other Unusual Items
-----0.66-
Pretax Income
-190.77-177.81-71.9-29.8-19.41-3.43
Net Income
-190.77-177.81-71.9-29.8-19.41-3.43
Net Income to Common
-190.77-177.81-71.9-29.8-19.41-3.43
Shares Outstanding (Basic)
554936555
Shares Outstanding (Diluted)
554936555
Shares Change (YoY)
25.20%34.13%600.33%3.67%7.64%-
EPS (Basic)
-3.49-3.66-1.99-5.77-3.89-0.74
EPS (Diluted)
-3.49-3.66-1.99-5.77-3.89-0.74
Free Cash Flow
--166.41-81.17-29.22-14.56-2.46
Free Cash Flow Per Share
--3.43-2.24-5.66-2.92-0.53
EBITDA
-203.01-192.36----
D&A For EBITDA
0.060.04----
EBIT
-203.07-192.4-84.66-31.48-18.73-2.94
Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q